U.S. stocks were lower, with the Dow Jones index falling over 200 points on Monday.

Shares of Kodiak Sciences Inc (NASDAQ:KOD) rose sharply after the company released data from the Phase 3 DAYBREAK trial for patients suffering from wet age-related macular degeneration (wAMD).

The study showed that both Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) achieved their primary endpoints.

Kodiak Sciences shares jumped 174% to $88.79 on Monday.

Here are some other big stocks recording gains in today’s session.

• SL Science Holding Ltd (NASDAQ:SLBT) gained 22% to $1.92.
• Chaince Digital Holdings Inc. (NASDAQ:CD) rose 18.2% to $6.30. Chaince Digital Holdings recently repurchased and permanently cancelled warrants for aggregate cash consideration of $2 million.
• YD Bio Ltd (NASDAQ:YDES) gained 18.1% to $6.77.
• Maase Inc. (NASDAQ:MAAS) rose 17.7% to $18.09.
• AMC Entertainment Holdings Inc (NYSE:AMC) rose 14.5% to $3.36 as investors continue to weigh a debt maturity extension and new alternative revenue streams.
• Falcon’s Beyond Global Inc (NASDAQ:FBYD) jumped 11% to $8.25.
• Pacific Biosciences of California Inc (NASDAQ:PACB) gained 10.5% to $1.79.
• Agenus Inc (NASDAQ:AGEN) gained 10.1% to $9.40 after Rodman & Renshaw initiated coverage on the stock with a Buy rating and announced a $19 price target.
• Burford Capital Limited (NYSE:BUR) rose 10% to $4.00 after the company announced a $1.4 billion entitlement if the patent case Taction Technology v. Apple payment was paid as is.
• Corporacion America Airports SA (NYSE:CAAP) jumped 9.2% to $26.07 after Argentina approved changes to Aeropuertos Argentina’s concession agreement to support infrastructure upgrades.
• MBX Biosciences Inc (NASDAQ:MBX) surged 8.2% to $58.05.
• Victoria’s Secret & Co (NYSE:VSXY) jumped 8.1% to $89.61.
• Howard Hughes Holdings Inc (NYSE:HHH) gained 7.5% to $73.58.
• Liquidia Corp (NASDAQ:LQDA) rose 6.7% to $73.02.
• Gap Inc (NYSE:GAP) gained 6.3% to $23.20.

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.